Commonwealth Equity Services’s CytomX Therapeutics CTMX Stock Holding History

Commonwealth Equity Services’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-53,243	Closed	-$121K	–	4274
2025 Q2	$121K	Sell	53,243 -1,000	-2%	-$1.61K	﹤0.01%	4029
2025 Q1	$34K	Buy	54,243 +1,000	+2%	+$775	﹤0.01%	4095
2024 Q4	$55K	Sell	53,243 -1,000	-2%	-$1.08K	﹤0.01%	3975
2024 Q3	$64K	Hold	54,243	–	–	﹤0.01%	3911
2024 Q2	$66K	Buy	54,243 +1,000	+2%	+$1.99K	﹤0.01%	3869
2024 Q1	$116K	Hold	53,243	–	–	﹤0.01%	3764
2023 Q4	$83K	Hold	53,243	–	–	﹤0.01%	3699
2023 Q3	$69K	Hold	53,243	–	–	﹤0.01%	3624
2023 Q2	$92K	Hold	53,243	–	–	﹤0.01%	3588
2023 Q1	$80	Hold	53,243	–	–	﹤0.01%	3525
2022 Q4	$85K	Buy	+53,243	New	+$78.8K	﹤0.01%	3437

Other funds holding CTMX

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Commonwealth Equity Services's CTMX Position: Q3 2025 in Review

Commonwealth Equity Services sold out of CytomX Therapeutics (CTMX) in Q3 2025, closing a stake of 53,243 shares — an estimated $121K sold.

Commonwealth Equity Services first reported a position in CTMX in Q4 2022 and held it in 11 quarters. The position peaked at $121K in Q2 2025. 103 funds tracked by Wall St. Rank hold CTMX as of Q3 2025.

Commonwealth Equity Services reported no remaining CytomX Therapeutics position as of Q3 2025 after selling out during the quarter.
Commonwealth Equity Services sold 53,243 CytomX Therapeutics shares in Q3 2025, an estimated $121K.
Commonwealth Equity Services first reported a position in CytomX Therapeutics in Q4 2022 and held it in 11 quarters.
Commonwealth Equity Services's CytomX Therapeutics position peaked at $121K in Q2 2025.
103 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2025.

Based on Commonwealth Equity Services's 13F filing for Q3 2025, filed 22 Oct 2025.